Logo image of EKSO

EKSO BIONICS HOLDINGS INC (EKSO) Stock Fundamental Analysis

NASDAQ:EKSO - Nasdaq - US2826443010 - Common Stock - Currency: USD

0.56  -0.01 (-1.75%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to EKSO. EKSO was compared to 189 industry peers in the Health Care Equipment & Supplies industry. EKSO has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, EKSO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

EKSO had negative earnings in the past year.
In the past year EKSO has reported a negative cash flow from operations.
In the past 5 years EKSO always reported negative net income.
EKSO had a negative operating cash flow in each of the past 5 years.
EKSO Yearly Net Income VS EBIT VS OCF VS FCFEKSO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

EKSO has a Return On Assets of -38.11%. This is in the lower half of the industry: EKSO underperforms 60.64% of its industry peers.
EKSO's Return On Equity of -74.86% is on the low side compared to the rest of the industry. EKSO is outperformed by 60.64% of its industry peers.
Industry RankSector Rank
ROA -38.11%
ROE -74.86%
ROIC N/A
ROA(3y)-37.12%
ROA(5y)-48.71%
ROE(3y)-69.61%
ROE(5y)-148.91%
ROIC(3y)N/A
ROIC(5y)N/A
EKSO Yearly ROA, ROE, ROICEKSO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600 -800

1.3 Margins

EKSO's Gross Margin of 51.84% is in line compared to the rest of the industry. EKSO outperforms 45.21% of its industry peers.
EKSO's Gross Margin has improved in the last couple of years.
EKSO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 51.84%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.54%
GM growth 5Y5.48%
EKSO Yearly Profit, Operating, Gross MarginsEKSO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300 -400

More info and screens

3

2. Health

2.1 Basic Checks

EKSO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, EKSO has more shares outstanding
EKSO has more shares outstanding than it did 5 years ago.
The debt/assets ratio for EKSO is higher compared to a year ago.
EKSO Yearly Shares OutstandingEKSO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M
EKSO Yearly Total Debt VS Total AssetsEKSO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

2.2 Solvency

EKSO has an Altman-Z score of -11.47. This is a bad value and indicates that EKSO is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of EKSO (-11.47) is worse than 80.32% of its industry peers.
EKSO has a Debt/Equity ratio of 0.28. This is a healthy value indicating a solid balance between debt and equity.
EKSO has a Debt to Equity ratio of 0.28. This is comparable to the rest of the industry: EKSO outperforms 50.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.28
Debt/FCF N/A
Altman-Z -11.47
ROIC/WACCN/A
WACC7.92%
EKSO Yearly LT Debt VS Equity VS FCFEKSO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M

2.3 Liquidity

A Current Ratio of 2.81 indicates that EKSO has no problem at all paying its short term obligations.
EKSO's Current ratio of 2.81 is in line compared to the rest of the industry. EKSO outperforms 52.13% of its industry peers.
EKSO has a Quick Ratio of 2.14. This indicates that EKSO is financially healthy and has no problem in meeting its short term obligations.
EKSO has a Quick ratio (2.14) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.81
Quick Ratio 2.14
EKSO Yearly Current Assets VS Current LiabilitesEKSO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

5

3. Growth

3.1 Past

EKSO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.96%, which is quite impressive.
The Revenue has been growing slightly by 4.13% in the past year.
EKSO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.04% yearly.
EPS 1Y (TTM)41.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.33%
Revenue 1Y (TTM)4.13%
Revenue growth 3Y27.21%
Revenue growth 5Y10.04%
Sales Q2Q%-10.38%

3.2 Future

The Earnings Per Share is expected to grow by 24.11% on average over the next years. This is a very strong growth
Based on estimates for the next years, EKSO will show a quite strong growth in Revenue. The Revenue will grow by 16.75% on average per year.
EPS Next Y53.64%
EPS Next 2Y33.84%
EPS Next 3Y24.11%
EPS Next 5YN/A
Revenue Next Year-1.84%
Revenue Next 2Y14.15%
Revenue Next 3Y16.75%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
EKSO Yearly Revenue VS EstimatesEKSO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M 20M 25M
EKSO Yearly EPS VS EstimatesEKSO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

EKSO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EKSO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EKSO Price Earnings VS Forward Price EarningsEKSO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EKSO Per share dataEKSO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

EKSO's earnings are expected to grow with 24.11% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.84%
EPS Next 3Y24.11%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EKSO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EKSO BIONICS HOLDINGS INC

NASDAQ:EKSO (2/11/2025, 12:31:17 PM)

0.56

-0.01 (-1.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-28 2024-10-28/amc
Earnings (Next)02-27 2025-02-27/amc
Inst Owners14.63%
Inst Owner Change-58.67%
Ins Owners7.02%
Ins Owner Change0%
Market Cap12.32M
Analysts82.5
Price Target5.61 (901.79%)
Short Float %7.32%
Short Ratio1.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.3%
Min EPS beat(2)1.96%
Max EPS beat(2)6.63%
EPS beat(4)2
Avg EPS beat(4)-27.51%
Min EPS beat(4)-96.08%
Max EPS beat(4)6.63%
EPS beat(8)3
Avg EPS beat(8)-13.22%
EPS beat(12)6
Avg EPS beat(12)-9.24%
EPS beat(16)8
Avg EPS beat(16)-8.75%
Revenue beat(2)0
Avg Revenue beat(2)-16.61%
Min Revenue beat(2)-27.08%
Max Revenue beat(2)-6.14%
Revenue beat(4)0
Avg Revenue beat(4)-14.98%
Min Revenue beat(4)-27.08%
Max Revenue beat(4)-0.43%
Revenue beat(8)3
Avg Revenue beat(8)-2.6%
Revenue beat(12)4
Avg Revenue beat(12)-0.89%
Revenue beat(16)6
Avg Revenue beat(16)-2.73%
PT rev (1m)0%
PT rev (3m)-12%
EPS NQ rev (1m)-6.67%
EPS NQ rev (3m)-6.67%
EPS NY rev (1m)-2.04%
EPS NY rev (3m)-2.04%
Revenue NQ rev (1m)-4.71%
Revenue NQ rev (3m)-4.71%
Revenue NY rev (1m)-1.38%
Revenue NY rev (3m)-1.38%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.7
P/FCF N/A
P/OCF N/A
P/B 0.83
P/tB 1.26
EV/EBITDA N/A
EPS(TTM)-0.65
EYN/A
EPS(NY)-0.23
Fwd EYN/A
FCF(TTM)-0.46
FCFYN/A
OCF(TTM)-0.45
OCFYN/A
SpS0.8
BVpS0.68
TBVpS0.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -38.11%
ROE -74.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 51.84%
FCFM N/A
ROA(3y)-37.12%
ROA(5y)-48.71%
ROE(3y)-69.61%
ROE(5y)-148.91%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.54%
GM growth 5Y5.48%
F-Score5
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 0.28
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.34%
Cap/Sales 0.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.81
Quick Ratio 2.14
Altman-Z -11.47
F-Score5
WACC7.92%
ROIC/WACCN/A
Cap/Depr(3y)13.77%
Cap/Depr(5y)10%
Cap/Sales(3y)0.95%
Cap/Sales(5y)0.66%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.33%
EPS Next Y53.64%
EPS Next 2Y33.84%
EPS Next 3Y24.11%
EPS Next 5YN/A
Revenue 1Y (TTM)4.13%
Revenue growth 3Y27.21%
Revenue growth 5Y10.04%
Sales Q2Q%-10.38%
Revenue Next Year-1.84%
Revenue Next 2Y14.15%
Revenue Next 3Y16.75%
Revenue Next 5YN/A
EBIT growth 1Y27.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y29.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y29.2%
OCF growth 3YN/A
OCF growth 5YN/A